Kaleido Biosciences, Inc. (KLDO): Price and Financial Metrics
KLDO Stock Summary
- Kaleido Biosciences Inc's stock had its IPO on February 28, 2019, making it an older stock than just 4.36% of US equities in our set.
- With a price/sales ratio of 307.94, Kaleido Biosciences Inc has a higher such ratio than 98.1% of stocks in our set.
- As for revenue growth, note that KLDO's revenue has grown 290% over the past 12 months; that beats the revenue growth of 97.74% of US companies in our set.
- Stocks that are quantitatively similar to KLDO, based on their financial statements, market capitalization, and price volatility, are EVGN, AGIO, SRRA, TBPH, and RARE.
- Visit KLDO's SEC page to see the company's official filings. To visit the company's web site, go to www.kaleido.com.
KLDO Stock Price Chart Interactive Chart >
KLDO Price/Volume Stats
|Current price||$7.07||52-week high||$20.50|
|Prev. close||$7.51||52-week low||$5.04|
|Day high||$7.55||Avg. volume||299,082|
|50-day MA||$10.14||Dividend yield||N/A|
|200-day MA||$8.59||Market Cap||300.24M|
Kaleido Biosciences, Inc. (KLDO) Company Bio
Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.
KLDO Latest News Stream
|Loading, please wait...|
KLDO Latest Social Stream
View Full KLDO Social Stream
Latest KLDO News From Around the Web
Below are the latest news stories about Kaleido Biosciences Inc that investors may wish to consider to help them evaluate KLDO as an investment opportunity.
Dan Menichella, Kaleido CEO, joins Yahoo Finance’s Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events. The treatment reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62% among patients with one or more comorbidity and about 51% overall. For patients with one or more comorbidity, KB109 reduced the median time to resolving the 13 overall COVID-19 symptoms from 30 to 21 days. The study also demonstrated a significant reduction in recovery time for patients aged 45 and older or with one or more comorbidity who received KB109 plus self-...
Kaleido Biosciences said on Wednesday its experimental oral treatment cut recovery time as well as hospitalizations and emergency room visits in patients with mild to moderate COVID-19, in an early trial. The treatment, KB109, reduced the total number of hospitalizations, emergency room visits, and urgent care visits by 51% in a study of 350 patients, and by 62% among patients with one or more co-morbidities, the company said. Kaleido said gut microbes can produce molecules that are believed to modulate such responses.
KLDO Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!